Intracranial administration of vaccinia virus complement control protein in Mo/Hu APPswe PS1dE9 transgenic mice at an early age shows enhanced performance at a later age using a cheese board maze test

Biogerontology

Volumn 9, Issue 6, 2008, Pages 405-420

  Kulkarni, Amod P ^a   Pillay, Nirvana S ^a   Kellaway, Lauriston A ^a   Kotwal, Girish J ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b InflaMed Inc   (United States)

Author keywords

Alzheimer's disease (AD); Amyloid; Cheese board maze; Complement; Thioflavine S; Vaccinia virus complement control protein; VCP

Indexed keywords

THIOFLAVINE; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; COGNITION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DRUG ACTIVITY; GENOTYPE; LEARNING; MAZE TEST; MOUSE; NONHUMAN; PARIETAL LOBE; PRIORITY JOURNAL; TASK PERFORMANCE; TRANSGENIC MOUSE;

AGE FACTORS; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; ANIMALS; ASSOCIATION LEARNING; BEHAVIOR, ANIMAL; COMPLEMENT SYSTEM PROTEINS; CONDITIONING (PSYCHOLOGY); DISEASE MODELS, ANIMAL; GENOTYPE; INJECTIONS; MAZE LEARNING; MICE; MICE, TRANSGENIC; REVERSAL LEARNING; SPACE PERCEPTION; THIAZOLES; VIRAL PROTEINS;

EID: 56049122419     PISSN: 13895729     EISSN: 15736768     Source Type: Journal    
DOI: 10.1007/s10522-008-9161-7     Document Type: Conference Paper

References (34)

1. Aisen P, Schafer K, Grundman M et al (2003) Alzheimer's disease cooperative study Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 289:2819-2826. doi: 10.1001/jama.289.21.2819
2. Bacskai B, Kajdasz S, Christie R et al (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7:369-372. doi: 10.1038/ 85525
3. Bussière T, Bard F, Barbour R et al (2004) Morphological characterization of Thioflavine S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Aβ immunotherapy on their clearance. Am J Pathol 65:987-995
4. Daly J, Kotwal G (1998) Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging 19:619-627. doi: 10.1016/S0197-4580(98)00100-6
5. Datta P, Rappaport J (2006) HIV and complement: Hijacking an immune defense. Biomed Pharmacother 60:561-568. doi: 10.1016/ j.biopha.2006.07.087
6. Fan R, DeFilippis K, Van Nostrand W (2007) Induction of complement proteins in a mouse model for cerebral microvascular Aβ deposition. J Neuroinflammation. doi: 10.1186/1742-2094-4-22
7. Gilbert P, Kesner R (2002) Role of the rodent hippocampus in paired-associate learning involving associations between a stimulus and a spatial location. Behav Neurosci 116:63-71. doi: 10.1037/ 0735-7044.116.1.63
8. Gonzalez-Velasquez F, Moss M (2008) Soluble aggregates of the amyloid-beta protein activate endothelial monolayers for adhesion and subsequent transmigration of monocyte cells. J Neurochem 104:500-513
9. Hicks R, Keeling K, Yang M et al (2002) Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J Neurotrauma 19:705-714. doi: 10.1089/08977150260139093
10. INT'Veld B, Ruitenberg A, Hofman A et al (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345:1515-1521. doi: 10.1056/NEJMoa010178
11. Isaacs S, Kotwal G, Moss B (1992) Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 89:628-632. doi: 10.1073/pnas.89.2.628
12. Izycka-Swieszewska E, Zółtowska A, Rzepko R et al (2000) Vasculopathy and amyloid beta reactivity in brains of patients with acquired immune deficiency (AIDS). Folia Neuropathol 38:175-182
13. Kotwal G, Moss B (1988) Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335:176-178. doi: 10.1038/335176a0
14. Kotwal G, Isaacs S, McKenzie R et al (1990) Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 250:827-830. doi: 10.1126/science.2237434
15. Kotwal G, Reynolds D, Keeling K et al (1998) Vaccinia virus complement control protein is a virokine with lysozyme-like heparin-binding activity: Possible implications in prolonged evasion of host immune response. In: Talwar GP, Nath I (eds) 10th International Congress of Immunology, New Delhi, India, pp 315-320
16. Kulkarni A, Kellaway L, Lahiri D et al (2004) Neuroprotection from complement-mediated inflammatory damage. Ann NY Acad Sci 1035:147-164. doi: 10.1196/annals.1332.010
17. Kulkarni A, Kellaway L, Kotwal G (2005) Herbal complement inhibitors in the treatment of neuroinflammation: Future strategy for neuroprotection. Ann NY Acad Sci 1056:413-429. doi: 10.1196/annals.1352.020
18. Lindahl U (2007) Heparan sulfate-protein interactions-a concept for drug design? Thromb Haemost 98:109-115
19. McKenzie R, Kotwal G, Moss B et al (1992) Regulation of complement activity by vaccinia virus complement-control protein. J Infect Dis 166:1245-1250
20. Minghetti L (2004) Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910
21. Murthy K, Smith S, Ganesh V et al (2001) Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104:301-311. doi: 10.1016/S0092-8674(01)00214-8
22. O'Callaghan P, Sandwall E, Li J et al (2008) Heparan sulfate accumulation with Aβ deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells. Brain Pathol [Epub ahead of print, Pubmed abstract]
23. Pillay NS, Kellaway L, Kotwal G (2007) Vaccinia virus complement control protein significantly improves sensorimotor function recovery after severe head trauma. Brain Res 1153:158-165. doi: 10.1016/ j.brainres.2007.03.056
24. Pillay NS, Kellaway L, Kotwal G (2008) Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer's disease model. Behav Brain Res. doi: 10.1016/ j.bbr.2008.03.038
25. Reines S, Block G, Morris J et al (2004) Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66-71
26. Reynolds D, Smith S, Zhang Y et al (2003) Vaccinia virus complement control protein modulates inflammation following spinal cord injury. Ann NY Acad Sci 1010:534-539. doi: 10.1196/annals.1299.099
27. Reynolds D, Smith S, Zhang Y et al (2004) Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann NY Acad Sci 1035:165-178. doi: 10.1196/ annals.1332.011
28. Scharf S, Mander A, Ugoni A et al (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53:197-201
29. Selkoe D (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81:741-766
30. Smith S, Mullin N, Parkinson J et al (2000) Conserved surface-exposed K/ R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin-binding sites and contribute to inhibition of molecular interactions with human endothelial cells: A novel mechanism for evasion of host defense. J Virol 74:5659-5666. doi: 10.1128/JVI.74.12.5659-5666.2000
31. Smith S, Sreenivasan R, Krishnasamy G et al (2003) Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance. Biochim Biophys Acta 1650:30-39
32. Speth C, Schabetsberger T, Mohsenipour I (2002) Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 76:3179-3188
33. Vorhees C, Williams M (2006) Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protocols 1:848-858. doi: 10.1038/nprot.2006.116
34. Yang F, Lim G, Begum A et al (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892-5901. doi: 10.1074/jbc.M404751200